NRF2-activating compounds have already been approved for the treatment of other diseases and were shown to be safe and efficient: dimethyl fumarate (Tecfidera®) is an oral medication approved for the treatment of remitting multiple sclerosis (Venci and Gandhi, 2013; Blair, 2019); fumaric acid esters (Fumaderm®) are used for the treatment of moderate to severe psoriasis and are also administered orally (Walker et al., 2014). This evidence concerns the gene NFE2L2 and psoriasis.